Bird Philip A, Begg Evan J, Zhang Mei, Keast Allan T, Murray Daran P, Balkany Thomas J
Department of Otolaryngology, Head and Neck Surgery, Christchurch Hospital, New Zealand.
Otol Neurotol. 2007 Dec;28(8):1124-30. doi: 10.1097/MAO.0b013e31815aee21.
To compare methylprednisolone concentrations in the perilymph of the human ear and in plasma after intratympanic (IT) or intravenous (IV) administration.
Methylprednisolone concentrations in the perilymph of patients during cochlear implantation were compared after 3 dosing strategies of methylprednisolone solution for injection (40 mg/ml): 1) IT administration of up to 40 mg was injected into the middle ear through the external auditory canal via a 27-gauge needle passed through a small anterosuperior myringotomy; 2) IV administration of 1 mg/kg was given as a single injection over 30 seconds; 3) IV administration of 10 mg/kg was infused over 30 minutes. Perilymph (single sample, approximately 20 microL) was sampled using a needle passed through the round window membrane, from 0.5 to 3 hours after dosing. In most patients, simultaneous blood sampling was performed. Methylprednisolone concentrations were measured by high-performance liquid chromatography with a limit of quantification of 0.001 mg/L.
In 39 patients studied, 33 perilymph samples were suitable for measurement, along with 26 plasma samples. Median perilymph concentrations were 6.7 mg/L (n = 18; range, 0.2-89.4 mg/L) after IT administration, 0.053 mg/L (n = 8; range, 0-0.47 mg/L) after IV injection of 1 mg/kg, and 0.2 mg/L (n = 7; range, 0.067-3.1 mg/L) after IV infusion of 10 mg/kg. The median perilymph concentrations were 126-fold higher after the IT administration than after 1 mg/kg IV (p = 0.0003) and 33-fold higher than after 10 mg/kg IV infusion (p = 0.0045). Plasma concentrations after IT administration were 16-fold lower than after IV administration of 1 mg/kg (p = 0.0006), and 136-fold lower than after IV infusion of 10 mg/kg (p = 0.0006).
IT administration of methylprednisolone in humans results in much higher perilymph concentrations and much lower systemic concentrations than IV administration.
比较鼓膜内(IT)或静脉内(IV)给予甲泼尼龙后人耳外淋巴液和血浆中甲泼尼龙的浓度。
比较注射用甲泼尼龙溶液(40mg/ml)3种给药策略后,人工耳蜗植入患者外淋巴液中甲泼尼龙的浓度:1)通过27号针头经外耳道穿过小的前上鼓膜切开术,将高达40mg的甲泼尼龙IT给药注入中耳;2)静脉注射1mg/kg,在30秒内单次给药;3)静脉输注10mg/kg,在30分钟内输注完毕。给药后0.5至3小时,使用穿过圆窗膜的针头采集外淋巴液(单个样本,约20μL)。在大多数患者中,同时进行血样采集。采用高效液相色谱法测定甲泼尼龙浓度,定量限为0.001mg/L。
在研究的39例患者中,33份外淋巴液样本和26份血浆样本适合测量。IT给药后外淋巴液中位浓度为6.7mg/L(n = 18;范围0.2 - 89.4mg/L),静脉注射1mg/kg后为0.053mg/L(n = 8;范围0 - 0.47mg/L),静脉输注10mg/kg后为0.2mg/L(n = 7;范围0.067 - 3.1mg/L)。IT给药后外淋巴液中位浓度比静脉注射1mg/kg后高126倍(p = 0.0003),比静脉输注10mg/kg后高33倍(p = 0.0045)。IT给药后的血浆浓度比静脉注射1mg/kg后低16倍(p = 0.0006),比静脉输注10mg/kg后低136倍(p = 0.0006)。
与静脉给药相比,人类IT给予甲泼尼龙可导致更高的外淋巴液浓度和更低的全身浓度。